Skip to main content

Seal Rock Therapeutics

October 17, 2023
Franciscan B
Multiple Therapeutics
Proven, clinical stage company discovering and developing first-in-class kinase inhibitors for diseases of the liver, kidney, and CNS. Lead program is phase 2-ready and will be evaluated in liver and/or kidney diseases. Recent $107 deal with Genfit, who will develop an IV formulation of Seal Rock's clinical-stage kinase inhibitor for acute-on-chronic liver disease.
Neil McDonnell - Seal Rock Therapeutics